Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ponatinib + cytarabine
- Development stage
- Phase 2
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ponatinib + cytarabine is a combination therapy used primarily in hematological malignancies. Ponatinib is a multi-target tyrosine kinase inhibitor that targets BCR-ABL including the T315I mutation, as well as VEGFR, PDGFR, FGFR, EPH receptors, KIT, RET, TIE2, and FLT3. Cytarabine is a cytotoxic antimetabolite that inhibits DNA synthesis. This combination has been studied in blast-phase chronic myeloid leukemia, FLT3-mutated acute myeloid leukemia, and Philadelphia chromosome-positive acute lymphoblastic leukemia.
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)BCR-ABL1 T315I (Bcr-Abl T315I mutant protein)DNA polymerase familyFGFR (Fibroblast growth factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFR (PDGFR family)RET (Rearranged during transfection receptor tyrosine kinase)TEK (Tie2)VEGFR (VEGFR family)
Beyond the preview
Go deeper on ponatinib + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ponatinib + cytarabine.